THIS s tudy w as des ign ed to ex am in e th
Introduction
Sinobronchial syndro me involve s the c oex iste nce of chronic rhino sinusitis , and chronic low er airw ay inflammation such as chronic bronchitis, bronchie ctasis and diffuse panbronchiolitis. In the tre atme nt and manage me nt of the dise as es, w e use mac rolide antib iotic s such as e rythromyc in, clarithro myc in and rox ithromycin (RXM), and satis fac tory re sults are obtaine d w hen the patie nts are give n the age nts in one -half the re commende d the rapeutic doses for more than 6 w eeks. 1 Although inve stigatio n of the me chanis ms of improve ment has suggeste d that it is not due to the anti-microbiological effe cts of the drugs, 2,3 the pre c ise mechanis ms are not w e ll unde rstood.
Many re ports cle arly de monstrate d that the macrolide antib iotic s, such as erythromycin and RXM, strong ly inhibit che motax is and gene ration of ox ygen radic als by polymorphonuc le ar le ukocyte s w hen the ce lls w e re culture d in v itro in the pre se nce of the macrolide s. [4] [5] [6] It is gene rally re cognized that T cells, espec ially he lper T ce lls, play an important role in the initiatio n and de velopment of inflammatory dise as es through the ir se cre tion of several types of cytokine s. Rec ently, w e have re p orte d that RXM strongly inhibits the produc tion of inf lammatory cytokine s, inte rleukin (IL)-3 and IL-4, from human periphe ral blood T ce lls in re sp ons e to in v itro stimulatio n w ith concanavalin A (Con A). 7 This inhibitory action of RXM on T-c ell cytokine production w as also obse rve d in v ivo : 8 the ability of spleen cells to produc e inflammatory T-c ell c ytokine s such as IL-5 w as signific antly suppre ssed w hen the cells w ere pre pare d from RXMpre tre ate d mice and culture d in v itro w ith Con A. From the se re p orts , it is re asonable to spe culate that orally adminis te re d mac rolide antib iotic s inhibit inflammator y re spons es via suppre ssion of T-ce ll cytokine production and re sults in an improve me nt of the clinic al status of the patie nts w ith sinobronchial syndro me.
Mac rophages play an important role in modulating the inf lammatory re sponse , by ac ting as scave nger ce lls for damage d tissue c ompone nts . The se cells also produc e several inflammatory c ytokine s, especially IL-1b and tumor ne crosis fac tor (TNF)-a . 9 How e ver, the e ffec t of RXM on mac rophages re mains unc lear.
We the re fore pe rforme d the pre sent study to answ er unre solved questions re garding the favorable effects of macrolide antib iotic s on inflammatory dis eases by ex amining the influenc e of RXM on mac rophage cytokine produc tion in vitro and in vivo .
Materials and methods

Mice
Spe cific pathogen-fre e, 5-w ee k-old, male BALB/c mic e w ere purchase d from Charle s Rive r Japan Inc . (Atsugi, Japan). To pre vent bacte rial and fungal airw ay infe ction, the y w ere housed in filte r-barrie re d cages and give n autoclave d food and tap w ate r a d libitu m throughout the ex pe rime nts .
Drugs
RXM w as kindly donate d from Hoe chst Mario n Roussel Co., Ltd., as a w ate r-insoluble pure p ow der. The age nt w as dissolved in me thyl alcohol at 50 mg/ ml and dilute d w ith phosphate buffere d-saline (PBS), so as to give a c onc entratio n of 1.0 mg/ml. This solution w as the n filte re d through a 0.22 m m filte r (Nihon Millipore Corp ., Yone zaw a, Japan) and store d as a stock solution at 4°C until use . For in v itro use , all dilutio ns w ere pre pare d from this stock solution by diluting w ith RPMI-1640 me dium supplemente d w ith 10% fetal calf serum, 10 mM HEPES, 2 3 10 -5 M 2ME (RPMI-FCS). Me tabolized RXM, RU28111, RU39001, RU44981 and RU45179 w e re also kindly supplie d by Hoechst Mario n Roussel Co., Ltd., as w ate r-insoluble pure pow de rs. The y w e re dissolved in RPMI-FCS, as in the case of RXM.
Preparation and purification of human peripheral blood monocytes
He pariniz ed pe riphe ral blood w as obtaine d from six he althy donors w ho gave w ritte n inform ed conse nt. The blood w as dilute d an e qual amount of 0.9% NaCl and ove rlaye re d on Lymphocyte s Separatio n Me dium (Organon Teknika, Durham, NC, USA). Afte r c entrifugatio n at 1500 rpm for 30 min at 25±2°C, the me dium -plasma inte rfac e, w hich c ontaine d mononuc lear c ells, w as colle cte d. The c ells locate d in this frac tion w ere w as hed five time s at 600 rpm at 25±2°C to re move plate le ts. The re sultant c ell suspension w as trans ferre d into plastic c ulture plate s and allow ed to attac h for 1 h at 37°C. The plate s w ere the n w as hed vigorously thre e times w ith RPMI-FCS to re move nonadhere nt ce lls. The adhe re nt c ells w ere colle cte d by sc raping w ith a rubber police man, w ashed onc e, re suspende d in RPMI-FCS at a c onc entratio n of 2 3 10 6 c ells/ml, and used as human peripheral blood monocyte s (PBM). The viability of ce ll populatio n ex c eeded 98%, as judge d by trypan blue ex clusion, and pe rox idase staining re veale d that more than 95% of c ells w e re monoc yte s.
Preparation of culture supernatant
An aliquot of c ells (1.0 ml) w as intro duce d into each w ell of 24-w ell plate s c ontaining 1.0 ml of vario us conc entratio ns of agents and 2.0 m g/ml lipopolysaccharide (LPS) ex trac te d from Kle bs ie lla p n e u m on ia e (Sigma Pure Chemic als, St. Louis, MO, USA). Afte r inc ubatio n for 24 h, the supernatant w as c ollec te d afte r pelleting the c ells by ce ntrifugatio n at 2000 rpm for 10 min at 25±2°C. The supernatant w as store d frozen at -40°C until assaye d for cytokine conc entratio n.
Treatment of mice with RXM
Mic e w e re give n 2.5 mg/kg RXM onc e a day for 5, 7, 9, and 12 w ee ks via a stomach tube . In this ex pe riment, the daily dose w as one -half of the re c ommende d the rape utic dose in a patie nt w eighing 60 kg. The c ontrol mice orally re c eive d PBS alone . 
Preparation of aqueous airway and lung extract
Mic e w ere adminis te re d an intrap erito ne al inje ction of p entobarbital at a dose of 60 mg/kg body w e ight, 24 h afte r LPS inje c tion. Airw ay and lungs w ere re move d and inflate d w ith 1.0 ml PBS and homogenize d in 2.0 ml PBS using a glass tissue homogenize r for 60 s in an ic e-cold w ate r bath. The homogenate s w ere the n c entrifuge d at 20003 g for 60 min at 4°C. The supe rnatants w ere c ollec te d and use d for aqueous airw ay and lung ex trac t (ALE).
Assay for cytokines
The ac tivity of IL-1b and TNF-a in both culture supe rnatants and ALE w ere ex amine d using c ommercially availab le mouse cytokine enzyme-linke d immunosorbent as say (ELISA) Test Kits (Ge nZyme Corp., Cambridge , MA, USA). The ELISA w as performed in duplic ate according to the manufac ture r's re comme nde d proce dure .
Statistical analysis
A statis tic al e valuatio n of the data w as made w ith the Mann -Whitne y U te st.
Results
Inhibitory effects of RXM on cytokine secretion from PBM in vitro
To ex amine the influenc e of RXM on cytokine se cre tion from PBM in re sponse to LPS stimulatio n in v itro , PBM w ere c ulture d in the pre senc e of vario us conc entratio ns of RXM. As show n in Fig. 1 , RXM caused a dose-dep ende nt re duction of both IL-1b (A) and TNF-a (B) sec re tion from PBM in re sponse to LPS stimulatio n in vitro . This suppre ssion w as first observe d w hen the c ells w ere culture d in the pre senc e of RXM at a conce ntration of as little as 0.05 m g/ml. Sinc e it is re porte d that RXM administe re d orally into animals analyz ed into four diffe re nt me tabolize d mate rials , 10 the nex t ex perime nts w ere designe d to ex amine w hether me tabolize d RXM could also suppre ss c ytokine secre tion from PBM. The data in Fig. 2 clearly show that metabolize d RXM could suppre ss cytokine sec re tion from PBM in a dose-depende nt manne r. It is also indic ate d that suppre ssive activity of metabolize d RXM on IL-1b se cre tion ( Fig. 2A) is stronge r than that on TNF-a se cre tion (Fig. 2B ). 
Su ppre s s ive a ctiv ity o f rox ithro m y cin
Mediators
Influence of RXM on cytokine appearance in vivo
This study w as designe d to ex amine the in v ivo effects of RXM on c ytokine se cre tion. To do this , the firs t se t of ex pe rime nts w as carrie d out to inve stigate the influe nce of intratrac he al infusion of LPS on cytokine le ve ls in ALE. The optimal conce ntratio n of LPS for se cre tion of cytokine s into ALE w as first ex amine d by quantitation of IL-1b . The data in Fig. 3 show that as the c onc entratio n of LPS instille d is inc re as ed, the level of IL-1b in ALE also inc re ase s. The max imum le ve l of IL-1b in ALE w as observe d w ith the use of 1.0 m g/ml LPS, and the higher c onc entration w as inhibitor y (Fig. 3) . The kine tic s of IL-1b appearanc e in ALE w as ex amine d in the ne x t ex perime nts. Mic e w e re ins tille d intratrac heally w ith 1.0 m g/ml LPS in a volume of 0.1 ml. ALE w as pre pare d from five individual mice various hours post-instillatio n. Control ALE from five PBS-instille d mice w as similarly pre pare d. LPS instillation caused a rapid inc re ase in IL1b le vel, re aching a max imum 24 h late r, follow ed by a slow de cre ase (Fig. 4) . The final set of ex perime nts w as unde rtake n to ex amine the influenc e of RXM on cytokine appe aranc e in ALE. Mic e w ere orally administe re d w ith 2.5 mg/kg RXM onc e a day for vario us periods. During the course of RXM tre atme nt, mice w ere intratrac heally infuse d w ith 1.0 m g/ml LPS, and ALE w as pre pare d 24 h afte r LPS infusion.
As show n in Fig. 5A , short-te rm (w ithin 5 w ee ks) adminis tration of RXM into mic e did not influe nce the appearanc e of IL-1b in ALE induc ed by LPS stimulation. On the other hand, long-te rm (more than 7 w eeks) adminis tration of RXM dramatic ally suppre ssed the appe aranc e of IL-1b in ALE. The data in . 5B clearly show that the inf luenc e of RXM adminis tration on TNF-a appearanc e in ALE is similar to that in IL-1b : the leve l of TNF-a in ALE w as marke dly supp re sse d w hen donor mice w ere tre ate d orally w ith RXM for more than 7 w ee ks, but not w ithin 5 w e eks.
Discussion
The pre sent re sults cle arly demons trate that RXM and me tabolize d RXM strongly inhibit cytokine se cre tion from human PBM in re sponse to mitogenic stimulation in vitro , and that the minimum conc entratio n of agents that c ause s inhibitio n of cytokine secre tion is as little as 0.05 m g/ml (Figs 1 and 2 ).
Pharmac ologic al studie s re veale d rapid and complete absorption of RXM adminis te re d orally, re sulting in high plasma leve ls and in prolonge d half-life , sinc e the mac roc yc line of RXM is loc ally modifie d to pre ve nt inac tivatio n in gastric juice . 10 It is also re porte d that, afte r oral adminis tratio n, plasma levels of RXM w ere gradually inc re as ed and attaine d a plate au at a c onc entratio n of approx imate ly 10.0 m g/ml.
10 RXM in p lasma w as the n analyze d into four diffe re nt me tabolize d mate rials , and metabolize d mate rials ex c ept for tw o type s, RU44981 and RU45179, are ex c re te d into urine and fece s, 10 suggesting that an inc re as e in unme tabolized and hardy ex c re te d me tabolize d RXM may occ ur p rogre ssive ly. Together w ith the p re se nt re sults, it may be suggeste d that RXM inhibits human monocyte ac tivation, especially cytokine se cre tion, and he lps to favorably modify the clinic al conditio ns of patie nts w ith sinobronchial syndrome . How e ver, be fore draw ing the conclusion that the ability of RXM to inhibit c ytokine se cre tion is re sponsible for the bene fic ial e ffec t of macrolide s on sinobronchial syndro me, it is ne cessary to ex amine w hether suppre ssive ac tivity of RXM on cytokine se cre tion c ould also be observe d in vivo .
Endotox ins, LPS compone nts of gram-ne gative bacte ria, are know n to be important stimuli in the development of inflammatory re sponse s. 11, 12 Pauw els e t a l. re porte d that inhalatio n of ae rosolized e ndotox in causes pulmonar y inflammatory re sponses in rats. 13 It has also be en re porte d that e ndotox ins c an stimulate vario us inflammatory ce lls, inc luding macrophages, and may induc e the re lease of a varie ty of inflammator y mediato rs, such as IL-1b and TNFa . [11] [12] [13] The re fore , w e used an e ndoto x in/mouse syste m and carrie d out the nex t ex perime nts. The data in Figs 3 -5 clearly de monstrate that intratrac heal inje ction of LPS cause s the appe aranc e of inflammatory cytokine s in airw ays and lungs, w hich w as inhibite d by pre tre atment of mic e w ith RXM. The se re sults may sugge st that RXM orally adminis te re d into mic e inhibits inflammatory c ytokine sec re tion in airw ays and re sults in atte nuating e ffec ts on sinobronchial syndro me.
Although the pre sent re sults sugge st that macrolide antib iotic s inhibit macrophage activatio n, e spec ially cytokine se cre tion, and re sult in a favorab le modific ation of the clinic al status of patie nts w ith sinobronchial syndrome , the me chanisms by w hich RXM inhibits c ytokine se cre tion in vitro and in v ivo are not cle ar at pre se nt. It is possible that RXM binds to re c eptors such as immunophillin, w hich is the intrac e llular re c eptor of immunosupre ssive agents FK-506 and rapamyc in, and the complex e s inte rfe re w ith cytokine gene trans c ription, 14, 15 re sulting in inhibition of cytokine sec re tion. This suggestion may be supporte d by our pre vious ex pe riments show ing that RXM c ould suppre ss mRNA ex pre ssion of TNF-a in human pe riphe ral blood monocyte s w he n the cells w ere c ulture d in vitro w ith the agent. 16 Furthermore , our unp ublishe d data also re veale d the inhibitory action of RXM on macrophage grow th and maturatio n from its pre cursors in v itro , suggesting that inhibition of in vivo mac rophage cytokine secre tion by RXM may be due to, at least partly, its suppre ssive ac tivity on macrophage grow th. In any c as e, more in-dep th analys is of the re latio nship betw ee n inhibitio n of se cre tion of inflammatory mediato rs by mac rolide s and inflammatory re sponses should allow us to ide ntify the pre cise mechanis ms involve d in the therapeutic mode of action of mac rolide s on sinobronchial syndro me.
